Abstract
The objective of this study was to evaluate if there are early clinical parameters in AS patients treated with three standard infusions of infliximab, which would predict whether a patient will derive a significant improvement at the tenth week, or whether there will be a lengthy clinical response after discontinuing the infusions. Sixty three AS patients were given three infusions of 5 mg/kg of infliximab at weeks 0, 2, and 6 and evaluated serially before each infusion and also at week 10. Afterwards, patients were followed up by telephone interview until their disease activities were >60% of the baseline values. At that point, disease was considered to have relapsed. Clinical parameters at baseline as well as at week 2 were used for analysis to identify factors that might predict an improvement at week 10, or predict a delayed relapse. A predictor is regarded as being useful if the area under the curve (AUC) when analyzed by receiver operator calculations (ROC) exceeds 0.75. No parameters at baseline have sufficient predictive values. However, ASAS20 (Assessment in Ankylosing Spondylitis International Working Group criteria) at week 2 predicts improvement at week 10, and also duration of clinical response after discontinuing the infliximab at week 6. The response to one pulse of infliximab is the best predictor of subsequent response as well as rate of relapse after discontinuing the infliximab.
Similar content being viewed by others
References
Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L et al (2003) Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48:1667–1675
Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187–1193
van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52:582–591
Breban M, Vignon E, Claudepierre P, Devauchelle V, Wendling D, Lespessailles E et al (2002) Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford) 41:1280–1285
Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G et al (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7:R439–R444
Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291
van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368
Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285
Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A (1994) Defining spinal mobility in ankylosing spondylitis (AS). The bath AS metrology index. J Rheumatol 21:1694–1698
Mander M, Simpson JM, McLellan A, Walker D, Goodacre JA, Dick WC (1987) Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 46:197–202
Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M (2001) Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44:1876–1886
Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J (2004) Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 63:665–670
Davis JC Jr, Van der Heijde DM, Dougados M, Braun J, Cush JJ, Clegg DO et al (2005) Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. J Rheumatol 32:1751–1754
Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M et al (2003) International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62:817–824
Acknowledgements
The 12-week clinical trial was supported by Xian-Janssen, Beijing, China. The follow-up study after week 12 was supported in part by the National Natural Science Foundation of China research grant # A30571726.
Conflict of interest statement
None of the authors have received any honoraria or consulting fees from Centocor or Xian-Janssen, Beijing, China or own any of their stocks.
Author information
Authors and Affiliations
Corresponding author
Additional information
Feng Huang and Jian Zhu have contributed equally to this project.
Rights and permissions
About this article
Cite this article
Huang, F., Zhu, J., Zhang, L. et al. Response to one infusion predicts subsequent improvement as well as the rate of relapse of ankylosing spondylitis infused with three pulses of infliximab. Clin Rheumatol 26, 920–926 (2007). https://doi.org/10.1007/s10067-006-0434-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-006-0434-8